Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,101 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Osteoarthritis Knee Pain
Interventions: SL1002, Normal Saline; Drug
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Roseville, California • San Diego, California • Greenwood Village, Colorado + 19 more

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: ABI-009, Gemcitabine; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: GERD
Interventions: Aluvra™, Saline; Device · Drug
Lead sponsor: Impleo Medical Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more

Conditions: Stress Urinary Incontinence
Interventions: lidocaine with epinephrine, Normal saline with epinephrine; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Bethel Park, Pennsylvania • Jefferson Hills, Pennsylvania • Pittsburgh, Pennsylvania + 1 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Arterial Catheterization
Interventions: Lidocaine/tetracaine patch, Placebo Patch, Subcutaneous injection of 0.5 ml Lidocain 1%, Subcutaneous injection of saline; Drug
Lead sponsor: Medical University of Vienna; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pain, Postoperative, Opioid Use
Interventions: Bupivacaine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Major Depression
Interventions: Botox, Saline Solution; Drug
Lead sponsor: Capital Clinical Research Associates, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chevy Chase, Maryland • Rockville, Maryland

Conditions: Healthy
Interventions: HEPLISAV, Engerix-B; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 8,374 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more

Conditions: Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions: Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid; Drug · Dietary Supplement
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 11 more

Conditions: Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions: Exparel (Bupivacaine Liposome), Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lumbar Disc Disease
Interventions: BRTX-100, Saline; Biological · Drug
Lead sponsor: BioRestorative Therapies; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more

Conditions: Rotator Cuff Tears, Rotator Cuff Tendinitis, Rotator Cuff Impingement, Injections, Glucocorticoids
Interventions: FX006 Injection; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 40 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions: PBA-0405; Drug
Lead sponsor: Pure Biologics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Osteoarthritis
Interventions: hyaluronate intra-articular injection, placebo injection; Device
Lead sponsor: Henry DeGroot, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Tibial Meniscus Injuries, Knee Injuries, Knee Injuries and Disorders
Interventions: Lipogems, Normal Saline; Device · Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Fasciitis, Plantar
Interventions: Micronized dHACM, Saline Injection; Other · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Tucson, Arizona • Carlsbad, California • Carmichael, California + 14 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, AIN 457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Postoperative Pain
Interventions: HTX-011, Saline Placebo, Bupivicaine HCl, Ropivacaine; Drug
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 24
States / cities: Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 13 more

Conditions: Thyroid Eye Disease
Interventions: Teprotumumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more

Conditions: Polymorphism-Genetic, Pain, Addiction
Interventions: Morphine, Placebo; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pediatric Intestinal Failure
Interventions: KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution; Device
Lead sponsor: SterileCare Inc.; Industry
Eligibility: 4 Weeks to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more

Conditions: Bacterial Infections
Interventions: XNW4107, Imipenem/Cilastatin, placebo; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy
Interventions: V118E, PREVNAR 20™, Saline; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Hallandale, Florida • South Miami, Florida • Springfield, Missouri + 1 more

Search by objective public record fields.

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Novel Endoluminal Clinical TreAtment of Reflux

The Impact of Retropubic Lidocaine vs Saline on Postoperative Urinary Retention Following Midurethral Sling

PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial

Rapydan Topical Anaesthesia for Arterial Cannulation

Intra-operative Uterosacral Ligament Bupivacaine Injection During Minimally Invasive Hysterectomy

Efficacy Study of Botox for Depression

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

A Double-blind RCT of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle

Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

Safety and Efficacy of AIN457 in Noninfectious Uveitis

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Genetic Effects on Dopamine Response to an Opiate

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

A Study of V118E in Healthy Participants (V118E-003)